[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367616-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367616-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","hpv-cancer-burden-by-anatomical-site-country-and-region-in-2022","HPV cancer burden by anatomical site, country, and region in 2022","","HPV vaccination can prevent over 90% of HPV infection-related cancers, making epidemiological burden assessments essential for improving vaccination and HPV-based screening programs. Using GBD 2021, GLOBOCAN 2022, and CI5Plus, the study estimates global burden for multiple HPV-associated cancers and quantifies HPV infection’s relative contribution. Joinpoint and piecewise regressions define time trends and APC, while Bayesian age-period-cohort modeling projects to 2045. Incidence and mortality are stratified by sex, age, and geography, with inequality analyses by SDI and HDI.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/hpv-cancer-burden-by-anatomical-site-country-and-region-in-2022/367616/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/hpv-cancer-burden-by-anatomical-site-country-and-region-in-2022/367616.png","ImageObject",300,407,{"name":42,"@type":43},"Chumphorn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Which data sources were used to evaluate HPV-related cancer burden in 2022?","Question",{"text":63,"@type":64},"The analysis used GBD 2021, GLOBOCAN 2022, and CI5Plus to estimate global burden for HPV-associated cancers and HPV’s relative contribution.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were time trends and future burden projections calculated?",{"text":68,"@type":64},"Time trends and annual percentage changes were derived using Joinpoint regression and piecewise linear regression, and future burden through 2045 was predicted with the Bayesian age-period-cohort (BAPC) model.",{"name":70,"@type":61,"acceptedAnswer":71},"What major burden levels were attributed to HPV infection in 2022?",{"text":72,"@type":64},"In 2022, approximately 831,204 cancer cases and 422,935 deaths were attributed to HPV infection, with cervical cancer representing the largest share of cases.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367616,1790217989,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nHPV cancer burden by anatomical site, country, and region in 2022  \nJingyuan Zhang1,5, Yong Ke2,5, Chi Chen1,5, Zhihao Jiang1, Heng Liu3, Yanhong Liu4􀀍 & Hong Cao1􀀍  \nHPV vaccination can prevent more than 90% of HPV infection-related cancers. Understanding the epidemiological burden of HPV-related cancers can better promote HPV vaccination and HPV-based screening programs. We used three databases—Global Burden of Disease 2021 (GBD2021), Global Cancer Observatory 2022 (GLOBOCAN2022), and Cancer Incidence in Five Continents Plus (CI5Plus)—to evaluate the global disease burden of cervical cancer, penile cancer, vulvar cancer, vaginal cancer, laryngeal cancer, oropharyngeal cancer, oral cancer, anal cancer, and the relative contribution of HPV infection. We used the Joinpoint regression model and piecewise linear regression to calculate the time trend and annual percentage change (APC). We combined it with the Bayesian age-periodcohort (BAPC) model to predict the disease burden in 2045. Age-standardized incidence rate (ASIR) and age-standardized mortality rate (ASMR) were stratified by sex, age, and geographic location. In addition, we conducted health inequality analyses across different sociodemographic index (SDI) and human development index (HDI) regions. In 2022, approximately 831,204 cancer cases (11.4% in men, 88.6% in women) and 422,935 deaths (10.4% in men, 89.6% in women) will be attributed to HPV infection, with cervical cancer accounting for the largest proportion (75.6% of cases). The country with the highest ASIR for HPV cancer was Eswatini (77.4/100,000), and the highest ASMR was Eswatini (52.1/100,000). Asia accounts for 57.8% of global HPV-related cancer cases, while Europe and Africa contribute 15.4% and 11.3%, respectively. From 1990 to 2021, the ASIR andASMR for cervical and certain head and neck cancers showed a declining trend, with AAPCs of − 0.33% and − 1.38% . Significant regional differences in the temporal trends inASIR for other anogenital cancers existed from 1983 to 2017. Risk factors such as smoking and unsafe sex are the main attributable factors for many cancers. The absolute number of HPV infection-related cancers will continue to rise. Given that the combined strategy of HPV vaccination and screening is cost-effective for nearly all countries, resources should be prioritized for cancer prevention programs targeting HPV infection. Especially in low-SDI areas, primary prevention targeting risk factors combined with secondary prevention can significantly reduce the overall incidence of cancer and avoid deaths due to late diagnosis.  \nCancer ranks as one of the primary causes of death among middle-aged and older individuals worldwide. Its associated chronic pain, diminished quality of life, and the substantial medical expenses of late-stage treatment impose a considerable burden on public health systems1,2. While traditionally classified as a noncommunicable disease, increasing evidence suggests that certain cancers are strongly linked to viral infections. Notably, human papillomavirus (HPV), a high-risk virus, is recognized as a significant causative agent in several cancers, including cervical, laryngeal, and oral cancers3,4. HPV-associated cancers display distinct clinical and epidemiological features, such as gender differences and specific age distributions5. For example, studies indicate that, unlike conventional age-related cancers, the peak incidence of cervical cancer now occurs before the age of 506. Despite the well-established causal relationship between HPV infection and these cancers, this link is often overlooked, primarily due to limited early screening coverage and disparities in healthcare resource allocation7,8. Importantly, cancers linked to HPV are highly preventable9. Expanding HPV vaccination programs and establishing comprehensive screening systems have the potential to significantly reduce the inc","cbCaiqidIhISAprv","https://ap.wps.com/l/cbCaiqidIhISAprv","pdf",2010142,11,"English","# HPV cancer burden estimation in 2022\n## Data sources and modeling approach\n## Incidence, mortality, and inequality analyses\n## Key findings and prevention implications","[{\"question\":\"Which data sources were used to evaluate HPV-related cancer burden in 2022?\",\"answer\":\"The analysis used GBD 2021, GLOBOCAN 2022, and CI5Plus to estimate global burden for HPV-associated cancers and HPV’s relative contribution.\"},{\"question\":\"How were time trends and future burden projections calculated?\",\"answer\":\"Time trends and annual percentage changes were derived using Joinpoint regression and piecewise linear regression, and future burden through 2045 was predicted with the Bayesian age-period-cohort (BAPC) model.\"},{\"question\":\"What major burden levels were attributed to HPV infection in 2022?\",\"answer\":\"In 2022, approximately 831,204 cancer cases and 422,935 deaths were attributed to HPV infection, with cervical cancer representing the largest share of cases.\"}]","HPV cancer burden by anatomical site, country, and region in 2022 | PDF",1790171634,28]